Antibody-dependent cellular cytotoxicity (ADCC) is one means by which macrophages (as well as natural killer cells and granulocytes) elicit a cytotoxic response. This is achieved via interaction of the Fc-g-receptor (CD64) with the Fc portion of antibody bound to target cells. We have created a chimeric CD64 molecule that incorporates a single chain Fv molecule, targeted against human carcinoembryonic antigen (CEA), fused to the membrane spanning and cytosolic domains of human CD64. Following adenoviral transfer to primary human monocytes, this chimeric CD64 receptor induced antigen-specific cytokine secretion during culture on immobilised CEA protein or on CEA-expressing tumour cells. Moreover, CEA targeted, but not control, monocytes effectively retarded CEA-positive tumour cell growth in vitro. Importantly, targeted monocyte cultures significantly reduced in vivo tumour growth rates in xenograft studies resulting in improved survival rates over that of control monocyte cultures. These data suggest that genetically directing monocytes against tumour antigens may be a useful means of achieving an immunotherapeutic response. Gene Therapy (2006) 13, 602-610.
Introduction
Macrophages constitute an important component of the innate immune system playing a key role in linking innate immunity with the adaptive immune system. Immature monocytes generated in the bone marrow migrate to multiple tissues in the body, where they can mature into macrophages and exert their influence through the production of cytokines and by cellular activities including cytotoxicity. Importantly, macrophages are known to heavily infiltrate tumours where they are referred to as tumour-associated macrophages (TAMs, reviewed in Bingle et al. ). However, the presence of high numbers of TAMs in tumours is associated with a poor clinical prognosis, suggesting that TAMs possess powerful mechanisms to traffic to tumour yet are unable to mount an effective antitumour immune response once congregated within the tumour.
The potent tumour infiltration of macrophages is a highly attractive property for exploitation as a cancer therapy. Previous studies have pre-activated monocyte/ macrophages ex vivo using potent cytokines (e.g. granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon gamma (IFNg)) or lipopolysaccharide (LPS) and have demonstrated that large numbers of these active cells (termed monocyte activated killer (MAK) cells) can be generated. 2, 3 In clinical trials, these adoptively transferred cells were well tolerated and showed good trafficking to sites of tumour. [2] [3] [4] [5] [6] [7] [8] Antibody-dependent cellular cytotoxicity (ADCC) is one mechanism that macrophages can employ for direct antitumour activity. [9] [10] [11] A requirement for ADCC is the generation of tumour-binding antibodies, which can be recognised by macrophages through their Fc receptors. Human macrophages express the Fc receptor specific for IgA (FC-a RI), and the high-and low-affinity Fc receptors for IgG (FC-g RI, FC-g RIIA, and FC-g RIIIA). It has been demonstrated that Fc-g receptors play a critical role in mediating tumour cytotoxicity in vivo and enhancement of FC-gR-mediated ADCC by inflammatory cells is a key step in development of effective immunotherapeutics. 12 The high-affinity FC-g RI (CD64: reviewed in Ravetch and Bolland 13 ) has been shown in experimental systems to efficiently mediate cytotoxic killing of tumour cell targets. Interaction of FC-g RI with the Fc portion of tumour cell-bound antibodies activates a signalling cascade, which results in target-cell killing by macrophages. This cytotoxic activity may be induced in vitro and in vivo through the administration of bi-specific antibodies, capable of binding both FC-g RI and a membrane antigen on target cells. 14, 15 Moreover, macrophage-mediated cell killing can also be induced by fusion proteins comprised of anti-FC-g RI and a tumourbinding ligand such as EGF. 16 However, the clinical efficacy of such bi-specific targeting molecules may be attenuated by a number of factors: the need for large amounts of recombinant protein product; problems of access of macromolecules to poorly vascularised tumours or those protected by the blood-brain barrier; the effects of plasma peptidase activities or immune responses to recombinant protein.
For these reasons, we have investigated a means of genetically intervening in the ADCC pathway with a view to enhancing the activity of activated monocyte/ macrophages specifically against tumour cells. We investigated whether adenoviral gene transfer of a chimeric FC-g-RI receptor (consisting of a single chain Fv (scFv) directed against the tumour associated antigen carcinoembryonic antigen (CEA) fused to a truncated form of CD64) in GM-CSF activated primary human monocytes resulted in controlled, antigen-specific activation of the monocytes. Importantly, whether these targeted monocytes could result in the specific impairment of the growth of CEA expressing tumour lines both in vitro and in vivo was investigated.
Results
Construction and expression of chimeric scFv-CD64 receptor in cultures of primary human monocytes A cDNA was constructed, which encoded a modified chimeric Fc-g-R1 receptor. The receptor consisted of the CEA-specific scFv MFE23, 17 and includes the cytosolic and transmembrane domains with part of the extracellular domain of human Fc-g-receptor I (CD64, amino acids Gly 256 to Thr 374 , Figure 1a ). The cDNA encoding the chimeric Fc-g-receptor was introduced into a firstgeneration recombinant adenoviral vector and expressed under the control of the human cytomegalovirus (hCMV) promoter (RAd.MFE23.hFc.CD64). A control GFP marker gene containing recombinant adenoviral vector (RAd.GFP -titre 2.6 Â 10 9 PFU/ml) or RAd. MFE23.hFc.CD64 (titre 1.3 Â 10 11 PFU/ml) were used to transduce GM-CSF stimulated monocytes derived from human peripheral blood mononuclear cells (PBMCs) by plastic adherence and subsequent 2 day stimulated with recombinant GM-CSF (10 ng/ml). After a further 48 h incubation, efficient expression of GFP or the chimeric Fc receptor was observed (Figure 1b) . A transduction of frequency of 480% was routinely achieved with an MOI of 100 (results generated from a minimum of three experiments with chimeric receptor adenovirus and at least four experiments using the GFP vector). Analysis of CEA-targeted human monocyte cultures specifically produce cytokines in response to immobilised protein antigen or CEA expressing tumour cell lines
In order to determine whether the expression of a chimeric receptor could induce antigen-specific functional responses in GM-CSF stimulated cells, monocyterich cultures from three healthy donors transduced with either RAd.GFP or RAd.MFE23.hFc.CD64 were cultured for 3 days on plates coated with either CEA protein or bovine serum albumin (BSA) and cell-free culture supernatants analysed for the presence of TNF-a.
Cell cultures transduced with the RAd.GFP vector failed to produce significant levels of TNFa when cultured on CEA or BSA protein (Figure 2a and b, respectively). In contrast, cell cultures from all three donors transduced with the CD64 chimeric receptor produced readily detectable levels of TNFa (Figure 2a) . Indeed, chimeric receptor expressing monocytes produced high levels of TNFa when cultured on plastic wells coated with CEA down to a coating concentration of 1 ng/ml, while RAd.GFP transduced monocytes failed to produce TNFa in response to CEA coated up to 10 mg/ml (data not shown). Importantly, the specificity of this response was confirmed through the low background levels of TNFa detected when the same cultures were cultured on BSA protein (Figure 2b) .
We next investigated whether targeted monocyte cultures could functionally respond to a CEA-expressing tumour cell line. Varying numbers of control, nontransduced and RAd.MFE23.hFc.CD64 transduced monocytes were cocultured with the gastric carcinoma cell line, MKN45K, which express CEA to high level and were further transduced with a GFP marker gene in order to facilitate the identification of the presence of tumour cells in coculture experiments by fluorescent microscopy. 18 In this set of experiments, nontransduced monocyte cultures were used as opposed to Rad.GFP control cultures, thereby avoiding detection issues with the GFP + tumour cells (see below).
After 3 days of coculture, a dose-dependent response was seen with the CD64 receptor expressing monocytes with TNF-a and IFN-g readily detected above an effector:target (E:T) ratio of 20:1 with a 29-fold increase of IFNg over the background levels produced by nontransduced monocytes observed at the 50:1 ratio ( Figure 3 ). In contrast, no significant production of either TNFa or IFNg was detected in untransduced monocytes except at the highest dose of effector monocytes (50:1) where 44 pg/ml of IFNg was detected ( Figure 3 ). These experiments taken together indicate that the MFE23.hFc.CD64 chimeric receptor when expressed in cultures predominantly composed of CD14 + monocytic cells could direct antigen-specific cytokine responses against purified protein antigen and against tumour cell lines. 
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Repression of in vitro tumour cell growth by targeted monocyte cultures
In order to assess whether transduced monocyte cultures could affect the growth of tumour cell lines in vitro, varying numbers of nontransduced or RAd.M-FE23.hFc.CD64 transduced monocyte populations were cocultured with GFP + MKN45K cells for 7 days at which point culture wells were analysed the presence of GFP + cells. This experiment was repeated three times with similar results obtained using three different donors. A representative experiment is shown ( Figure 4 ). There was a depletion of GFP + cells observed in wells where RAd.MFE23.hFc.CD64 monocytic cells were cultured at an E:T ratio of 20:1 with effectively no GFP + cells detected in wells where the E:T ratio was 50:1. However, at ratios of 10:1 and less, no significant effect on MKN45K cell growth was observed (Figure 4a ). In contrast, control, nontransduced monocytes failed to significantly inhibit the growth of MKN45K tumour cells at any of the effector:target ratios examined (maximum 50:1, Figure  4a ). Specificity of this activity was confirmed using tumour targets that lacked CEA expression. HeLa cells transduced with a GFP marker gene when cocultured with RAd.MFE23.hFc.CD64 transduced monocytes showed no evidence of reduced growth (as assessed by fluorescent microscopy) at E:T ratios up to 50:1 with some small evidence of nonspecific tumour cell line killing at E:T ratios greater than 75:1 (data not shown, experiments performed with three independent donors).
Analysis of the immunophemotype of the transduced cell population indicated that although the predominant cell type present was CD14 + and thus of monocyte/ macrophage origin, other cell types were represented, including CD56
+ natural killer (NK) cells and a very 
Antitumour activity of human monocytes expressing chimeric FC-g-receptors in vivo
Having demonstrated the antitumour activity of monocytes targeted to CEA, the effect of the modified cells on in vivo tumour growth was studied in nude mice xenografted with human MKN45K cells. Tumour cells were mixed with RAd.MFE23.hFc.CD64 infected monocytic cells at an E:T ratio of 1:1 and implanted subcutaneously. Tumour cells alone, as well as tumour cells mixed with monocyte cultures transduced with RAd.GFP at the same E:T ratio, were used as controls. Due to the relatively poor expansion of monocyte cultures, the number of animals per group was restricted to three (apart from in the experiment with Donor A where four animals were in the RAd.MFE23.hFc.CD64 group) and experiments were repeated three times on three separate occasions with transduced monocytes generated from three different donors.
Initial analysis focused on determining the length of time taken for tumours to reach a volume of 200 mm there was also some suggestion of slower tumour growth in RAd.GFP treated animals. However, when the data of the three experiments are combined ( Figure 5 , combined), no significant difference between the mean time to 200 m 3 was seen between the RAd.eGFP and saline groups (P40.1, n ¼ 9 for each group). In contrast, there was a clear slowing of tumour growth in RAd.MFE23.hFc.CD64 animals (n ¼ 7) compared with either RAd.eGFP (Po0.05, n ¼ 9) or saline (Po0.01, n ¼ 9) controls. The difference in tumour growth in animals that received targeted monocytes also translated into an improved survival. As shown in the survival plots in Figure 5 , there was no significant difference in the survival of saline and RAd.eGFP cohorts (P40.05, logrank test). In contrast, the majority of animals that received targeted monocytes survived longer than controls and, assessing the combined results of all three experiments, a highly significant increase in the survival of animals implanted with tumour cells and RAd.MFE23.hFc.CD64 infected monocytes was observed (log-rank test Po0.001).
Discussion
The aim of this study was to determine the potential of antigen-specific chimeric receptors to enhance the antitumour activity of cytokine activated monocyte/macrophages. Chimeric receptors based on T-cell signalling molecules expressed by recombinant retroviruses effectively direct the functional activities of T cells to target cells expressing the appropriate protein antigen. [19] [20] [21] [22] [23] [24] [25] Adopting this strategy to monocytes necessitated the use of recombinant adenoviruses due to the low proliferative nature of primary monocytes and, using this method, very high levels of transduction in GM-CSF treated, PBMCs were achieved. Furthermore, this study focused on the development of a novel Fc-g-R1 (CD64) receptor since activation of this receptor effectively stimulates the functional activities of monocytic cells. 13 The chimeric CD64 receptor was generated by the fusion of the CEA-specific MFE23 scFv with a truncated form of human CD64 protein. MFE23 has been used in in vivo imaging studies in rodents 26 and humans 27 and also functions well in T-cell-based chimeric immune receptors. 18, 28 Adenoviral transfer at a multiplicity of infection (MOI) of 100:1 resulted in high-level expression of the chimeric receptor in GM-CSF-stimulated primary human monocytes. Encouragingly, these cells responded by the production of proinflammatory cytokines only when cultured on the appropriate protein antigen or with antigen-expressing tumour cell lines in vitro, indicating that the activity of the gene-modified macrophages was effectively controlled by the chimeric Fc receptor with a high degree of specificity similar to that observed with other MFE23 scFv-based chimeric recpetors. 18, 28 This observation indicated that the crosslinked chimeric receptor effectively coupled with the necessary downstream effector signals in order to generate a functional cellular response.
Moreover, genetically-targeted, but not control cell cultures, elicited a substantial reductive effect on the growth of tumour cells in vitro while add back experiments suggested that the CD14 + monocytic cells were the Immunotherapy of cancer A Biglari et al principal cell line required for this activity. Importantly, while high effector:target ratios were required for in vitro activity, equivalent numbers of transduced monocytes had a significant retardation of tumour growth rates coupled with improved survival rates when coinjected with tumour in nude mice. This result is encouraging Immunotherapy of cancer A Biglari et al since it suggests that fewer cells may be required in a clinical situation than might be predicted by in vitro observation albeit given the limitations of the particular model system used here. One of these limitations is the limited expansion of monocytic cells ex vivo. These studies used monocytic cultures generated from relatively small blood samples and resulted in relatively modest numbers of cells for experimental study. Relevant numbers of cytokine stimulating monocytic cells have been generated for clinical trial application [2] [3] [4] [5] [6] [7] [8] and application of these technical methods will be required in order to perform more robust in vivo experiments. However, the basic assay described here clearly demonstrates proof of principle in that low numbers of antigenspecific monocytic cells can effectively modulate the growth of an aggressive tumour cell line in vivo.
These observations generate interesting questions concerning the mechanism that the monocytes effect an antitumour response. Although in vitro assays demonstrated that killing of tumour cells was dependent on the levels of targeted CD14 + cells and was inversely correlated with the levels of nonmonocytic cells, these particular assays involved long-term (seven day) coculture. No specific cytotoxicity was observed in short-term chromium release assay (Supplementary Figure 1) , suggesting that these transduced cell cultures did not utilise perforin-mediated mechanisms. This was not due to an intrinsic failing of the scFv-CD64 receptor since the same receptor performed adequately in chromium release assay when expressed in human T cells using retroviral gene transfer technology (Supplementary Figure 1) . Consequently, transduced CD14 + cells may potentially be acting in a direct manner through a variety of mechanisms, including the Fas pathway or may be acting indirectly through the recruitment of other immune effectors through cytokine signalling or through antigen-presentation/direct contact mechanisms. Indeed, within the experiments presented here,NK cells were present to varying levels in the in vitro coculture assays and the nude mouse possesses residual NK activity and so a potential mechanistic interaction between chimeric receptor bearing monocytic cells and NK cells is not discounted within this study. Consequently, further studies are required in order to more fully describe the antitumour mechanism detailed here.
However, with these points in mind, the future development of adenoviral transduction of monocytic cells would most likely involve combination with other immunotherapeutic strategies. For example, adoptively transferred antigen-specific T cells may benefit from the presence of monocytic cells actively producing proinflammatory cytokines at the site of tumour. To this end, the attraction of transduced monocytes is their potential trafficking to sites of hypoxia as found in solid tumour masses. 29 Moreover, previous studies using bispecific antibodies have shown accumulation of monocyte/ macrophages in tumours 30 while clinical studies using activated macrophages have shown effective localisation to tumour sites. 6 At present, it is unclear what effect adenoviral gene transfer or chimeric receptor gene expression will have on trafficking of the immune effector cells. With respect to the specific issue of targeting CEA, while effective tumour localisation by the MFE23 scFv in protein form has been demonstrated, 26 ,27 the potential effect of serum CEA remains unclear. Experiments using T cells armed with an MFE23 based chimeric receptor have confirmed that high levels of CEA did not appear to interfere with the in vitro targeting of CEA expressing target cells, 18 an observation also confirmed by other groups using different anti-CEA scFv's. 22 However, whether serum CEA can adversely interfere with the efficient trafficking of monocytes armed with an anti-CEA scFv in the clinical situation has yet to be determined. Generating suitable models coupled with more rigorous tumour systems will form an important focus with which to explore these issues and to determine whether synergies between immunotherapeutic strategies can be found.
Notwithstanding these considerations, our data, showing efficient adenoviral transduction and antigen directed activation of GM-CSF stimulated monocyte cultures and killing of tumour cells in vitro and in vivo, are encouraging and future studies will allow us to more fully assess the potential of this approach and to understand more fully the issues surrounding tumourspecific activation of monocytic function.
Materials and methods

MFE23.hFc.CD64 chimeric receptor cDNA
A full-length DNA clone for human CD64 (corresponding to Genbank sequence NM_00566) was generated by reverse-transcription PCR using RNA generated from PBMCs using the following primers: A fragment of CD64 encoding a truncated extracellular form of CD64, which encoded amino acids Gly 267 to Thr 374 , was amplified from the full-length clones using the primer CD64 forward: 5 0 -GGCCGGCCGGAAATGT CCTTAAGCGCAGCCCTGAGTTGGAGCTT-3 0 with the Fc reverse primer. The sequence of the amplified fragment was confirmed and he fragment inserted as a FseI/XbaI (restriction sites underlined in the relevant primer) into a pVOM shuttle vector processing the MFE23 scFv fused to the hinge, CH2 and CH3 regions of human IgG 1 (hFc 31 ).
Generation of recombinant adenoviruses
The MFE23.hFc.CD64 receptor cDNA was liberated as a HindIII-XbaI fragment and ligated into the adenoviral shuttle vector pAdlox. 32 GFP control adenoviral vector was generated by the subcloning of the eGFP cDNA (Clontech, Mountain View, USA) into the pAdlox vector. Recombinant adenoviral particles (hereafter termed RAd.MFE23.hFc.CD64 and RAd.GFP) were generated by cotransfection of CRE8 cells with the pAdlox vector and adenovirus C5 DNA as described. 32 High-titre stocks were prepared by double caesium chloride density gradient separation and titred as previously described. 33, 34 Viral stocks were found to be free of replication-competent adenovirus using a supernatant rescue assay using HeLa cells able to detect 1 replicationcompetent virus within 10 9 recombinant viruses. 2-mercaptoethanol and 2 mM glutamine). All growing cells were incubated in a humidified incubator containing 5% CO 2 at 371C.
Isolation, purification and adenoviral infection of PBMCs
Human PBMCs were isolated from healthy donors by centrifugation on a Histopaque gradient (1077; Sigma, Dorset, UK). The isolated PBMC were then washed twice with PBS, resuspended in modified RPMI and allowed to adhere to plastic tissue culture flasks for 60 min. The nonadherent cells were collected and adherent fraction (predominantly monocytes) was treated with 10 ng/ml human GM-CSF (R&D systems, UK) for 48 h in modified RPMI medium. Cells were then infected with adenoviral vectors diluted in RPMI supplemented with 2% heatinactivated FCS at various MOI for 12 h at 371C. Unbound virus was removed by two washes in phosphate-buffered saline (PBS) and cells were incubated for a further 48 h. Cell morphology gradually changed and approximately 4 days postisolation macrophage-like cells could be observed.
Antitumour activity of PBMCs in vitro
Human PBMCs, infected with RAd.MFE23.hFc.CD64 at a MOI of 100, were detached from the tissue culture flasks by EDTA disaggregation. Cellular viability was 495% as determined by Trypan blue exclusion. Cells were washed with PBS and cocultured with MKN45K cells retrovirally transduced to express eGFP (MKN45K.GFP, 3 Â 10 3 cells per well) in triplicate at varying Effector:Target (E:T) ratios (1:1 to 50:1) in a 48-well plate. Uninfected monocytes were used as controls. In experiments where CD14 + cells were depleted, CD14 + microbeads (Miltenyi biotec, Germany) were used in accordance with the manufacturer's instructions. One half of the medium in each well was exchanged with fresh every 48 h. Since the MKN45K cell line expressed GFP, tumour cell growth was evaluated using fluorescence microscopy using an inverted UV microscope (Zeiss AxioVert 35 M with image capture via a Zeiss Axiocam MRC and acquired through AxioCam software) and by flow cytometry.
Cytokine production assay
At appropriate time points, the medium from monocytes cultured with target cells was centrifuged and the cellfree supernatant was assayed for the concentrations of IFN-g and TNF-a by ELISA, according to the manufacturer's protocol (R&D, Abingdon, UK). Likewise, the cytokine profiles of transduced or control monocytes cultured in wells precoated with CEA protein (Calbiochem, Nottingham, UK) or BSA in borate buffer (pH 8.5) were analysed by ELISA.
Flow cytometry
Cells were washed with PBS containing 1% FCS and resuspended in saturating concentrations of antibody (anti-human IgG (Fc), anti-CD14, anti-CD3, anti-CD19 and anti-CD56 and suitable isotype controls (all antibodies used were direct conjugates to R-phycoerythrin); Pharmingen, Oxford, UK) on ice for 30 min. Cells were then washed twice with PBS containing 1% FCS, and analysed using a FACscan (Becton Dickenson, CA, USA) with winMDI version 2.8 analysis software.
In vivo studies
All animals were housed and maintained in strict accordance with the UK Animals (Scientific Procedures) Act 1986. Tumour cells, shortly before implantation, were mixed with RAd.MFE23.hFc.CD64 or RAd.GFP infected monocytes at an E:T ratio of 1:1 (or with an equivalent volume of saline) and implanted subcutaneously into the flank of nude mice. The number of animals per group was three and experiments were repeated three times with blood taken from different donors at different times. The animals were monitored daily with tumour growth measured using calliper measurements with tumour volume determined using the formula l Â w 2 Â 0.5 mm 3 , where l and w represent length and width tumour measurements. Animals were culled once the tumour reached a maximum size of 1.24 cm 3 or at the first evidence of ulceration or discomfort of the subject or at the time limit of 60 days.
Statistical analysis
Survival data were compared using the log-rank test. Tumour growth data were analysed using an unpaired, two-tailed Student's T-test, assuming unequal variance.
